Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

Parkinsonism and Related Disorders

Volumn 12, Issue 7, 2006, Pages 443-452

  Hjelmgren, Jonas ^a   Ghatnekar, Ola ^a   Reimer, Jan ^b   Grabowski, Martin ^b,c   Lindvall, Olle ^b   Persson, Ulf ^a   Hagell, Peter ^b,d  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Cell therapy; Cost effectiveness; Modeling; Outcomes; Parkinson's disease

Indexed keywords

DOPAMINE;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOPAMINERGIC NERVE CELL; FEMALE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; PARKINSON DISEASE; PRIORITY JOURNAL; PROFIT; QUALITY ADJUSTED LIFE YEAR; SIMULATION; TREATMENT OUTCOME; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DECISION MAKING; DISEASE PROGRESSION; DOPAMINE; GENE THERAPY; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; NEURONS; PARKINSON DISEASE; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION;

EID: 33748764131     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.04.006     Document Type: Article

References (44)

1. Bjarkam C.R., and Sørensen J.C. Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson's disease. Biol Psychiatry 56 4 (2004) 213-216
2. Rascol O., Payoux P., Ory F., Ferreia J.J., Brefel-Courbon C., and Montastruc J.L. Limitations of current Parkinson's disease therapy. Ann Neurol 53 Suppl 3 (2003) S3-S15
3. Emborg M.E., Deglon N., Leventhal L., Aebischer P., and Kordower J.H. Viral vector-mediated gene therapy for Parkinson's disease. Clin Neurosci Res 1 6 (2001) 496-506
4. Bensadoun J.C., Widmer H.R., Zurn A.D., and Aebischer P. Polymer-encapsulated cells as a tool for drug delivery and neural transplantation in Parkinson's disease. In: Krauss J.K., and Jankovic J. (Eds). Surgery for Parkinson's disease and movement disorders (2001), Lippincott Williams & Wilkins, Philadelphia 245-251
5. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat Med 9 5 (2003) 589-595
6. Lindvall O., Kokaia Z., and Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 10 Suppl (2004) S42-S50
7. Grabowski H. The effect of pharmacoeconomics on company research and development decisions. Pharmacoeconomics 11 5 (1997) 389-397
8. Annemans L., Genesté B., and Jolain B. Early modeling for assessing health and economic outcomes of drug therapy. Value Health 3 6 (2000) 427-434
9. Weinstein M., Toy E., Sandberg E., Neumann P., Evans J., Kuntz K., et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4 5 (2001) 348-361
10. Hoehn M.M., and Yahr M. Parkinsonism: onset, progression and mortality. Neurology 17 5 (1967) 427-442
11. Siebert U., Bornschein B., Walbert T., and Dodel R.C. Systematic assessment of decision models in Parkinson's disease. Value Health 7 5 (2004) 610-626
12. Statistics Sweden (Statistiska centralbyrån). Statistical yearbook of Sweden 2003 (in Swedish: Statistisk årsbok för Sverige 2003) (2002), Statistiska centralbyrån, Stockholm
13. Hely M.A., Morris J.G., Traficante R., Reid W.G., O'Sullivan D.J., and Williamson P.M. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67 3 (1999) 300-307
14. Schrag A., Selai C., Jahanshahi M., and Quinn N.P. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 69 1 (2000) 67-73
15. Schrag A., Jahanshahi M., and Quinn N.P. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15 6 (2000) 1112-1118
16. Dolan P., Gudex C., Kind P., and Williams A. Social tariff for EuroQol: results from a UK general population survey. Discussion Paper No. 138 (1995), University of York, Central for Health Economics, York
17. Hagell P., Nordling S., Reimer J., Grabowski M., and Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 17 6 (2002) 1213-1220
18. Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) (2003), Läkemedelsförmånsnämnden, Solna
19. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5 7 (2002) 627-628
20. Lindvall O., and Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 127 (2000) 299-320
21. Lindvall O., and Hagell P. Status of neural repair clinical trials in brain diseases. In: Selzer M.E., Clarke S., Cohen L.G., Duncan P.W., and Gage F.H. (Eds). Textbook of neural repair and rehabilitation. Neural repair and plasticity vol. I (2006), Cambridge University Press, Cambridge 615-631
22. Ghatnekar O., Persson U., Glader E.L., and Terént A. Cost of stroke in Sweden-an incidence estimate. Int J Technol Assess Health Care 20 3 (2004) 375-380
23. Spottke E.A., Volkmann J., Lorenz D., Krack P., Smala A.M., Sturm V., et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 249 6 (2002) 759-766
24. NICE-Working to a QALY threshold? Pharma Pricing & Reimbursement 2001;September:262-3.
25. Persson U., and Hjelmgren J. Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsa. Läkartidningen 100 43 (2003) 3436-3437
26. Eichler H.G., Kong S.X., Gerth W.C., Mavros P., and Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 7 5 (2004) 518-528
27. Dodel R.C., Singer M., Köhne-Volland R., Szucs T., Rathay B., Scholz E., et al. The economic impact of Parkinson's disease: an estimation based on a 3-month prospective analysis. Pharmacoeconomics 14 3 (1998) 299-312
28. Findley L., Aujla M., Bain P.G., Baker M., Beech C., Bowman C., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 18 10 (2003) 1139-1145
29. Keränen T., Kaakkola S., Sotaniemi K., Laulumaa V., Haapaniemi T., Jolma T., et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 9 3 (2003) 163-168
30. LePen C., Wait S., Moutard-Martin F., Dujardin M., and Ziégler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 16 1 (1999) 59-69
31. Coyle D., Barbeau M., Guttman M., and Baladi J.F. The economic evaluation of pharmacotherapies for Parkinson's disease. Parkinsonism Relat Disord 9 5 (2003) 301-307
32. Fayers P.M., and Hand D.J. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 350 9083 (1997) 1025-1027
33. Brennan A., and Akehurst R. Modelling in health economic evaluation. What is its place? What is its value?. Pharmacoeconomics 17 5 (2000) 445-459
34. Péchevis M., Clarke C.E., Vieregge P., Khoshnood B., Deschaseaux-Voinet C., Berdeaux G., et al., on behalf of the Trial Study Group. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12 12 (2005) 956-963
35. Müller J., Wenning G.K., Jellinger K., McKee A., Poewe W., and Litvan I. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 55 6 (2000) 888-891
36. Alves G., Wentzel-Larsen T., Aarsland D., and Larsen J.P. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65 9 (2005) 1436-1441
37. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., and Muenter M.D. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 39 9 (1989) 1187-1190
38. Diederich N.J., Moore C.G., Leurgans S.E., Chmura T.A., and Goetz C.G. Parkinson's disease with old age: a comparative study with subjects with middle-age onset. Arch Neurol 60 4 (2003) 529-533
39. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 3 (2003) 403-414
40. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 10 (2001) 710-719
41. Gordon P.H., Yu Q., Qualls C., Winfield H., Dillon S., Greene P.E., et al. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol 61 6 (2004) 858-861
42. Björklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2 7 (2003) 437-445
43. Freed C.R. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease. Proc Natl Acad Sci USA 99 4 (2002) 1755-1757
44. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., and Stoddart G.L. Methods for the economic evaluation of health care programmes. 3rd ed (2005), Oxford University Press, New York